
Codexis CDXS
$ 1.65
-1.2%
Quarterly report 2025-Q3
added 11-06-2025
Codexis DPO Ratio 2011-2025 | CDXS
Annual DPO Ratio Codexis
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 98.4 | 131 | 29.9 | 49 | 74.3 | 61.2 | 88.2 | 90.3 | 158 | 188 | 175 | 99.3 | 43.5 | 90.5 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 188 | 29.9 | 98.4 |
Quarterly DPO Ratio Codexis
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 72.1 | 163 | 148 | - | 83.5 | 94.2 | 88.5 | - | 145 | 123 | 78.1 | - | 12.2 | 7.89 | 26.5 | - | 42.8 | 71.1 | 70.7 | - | 74.4 | 160 | 100 | - | 47.2 | 86.3 | 58.9 | - | 73.4 | 107 | 78.7 | - | 81.4 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 163 | 7.89 | 83.7 |
DPO Ratio of other stocks in the Biotechnology industry
| Issuer | DPO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Arbutus Biopharma Corporation
ABUS
|
23 | $ 4.86 | 3.08 % | $ 807 M | ||
|
Aclaris Therapeutics
ACRS
|
887 | $ 3.22 | -1.08 % | $ 249 M | ||
|
Aptevo Therapeutics
APVO
|
239 | $ 1.05 | -7.08 % | $ 290 K | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
78.2 | - | - | $ 40.3 B | ||
|
Catalyst Biosciences
CBIO
|
18.8 | $ 13.58 | -3.62 % | $ 894 M | ||
|
Midatech Pharma plc
MTP
|
162 | - | -18.52 % | $ 27.3 M | ||
|
Celldex Therapeutics
CLDX
|
6.17 K | $ 27.1 | -1.51 % | $ 1.75 M | ||
|
Corcept Therapeutics Incorporated
CORT
|
550 | $ 88.16 | 0.19 % | $ 9.1 B | ||
|
Catalyst Pharmaceuticals
CPRX
|
83.2 | $ 24.27 | 2.75 % | $ 2.87 B | ||
|
Институт стволовых клеток человека
ISKJ
|
115 | - | - | - | ||
|
Acasti Pharma
ACST
|
4.39 K | - | 4.01 % | $ 150 M | ||
|
Albireo Pharma
ALBO
|
1.59 K | - | -0.23 % | $ 916 M | ||
|
Dynavax Technologies Corporation
DVAX
|
52.8 | $ 10.8 | - | $ 1.4 B | ||
|
Ampio Pharmaceuticals
AMPE
|
2.85 K | - | -11.43 % | $ 502 K | ||
|
Amphastar Pharmaceuticals
AMPH
|
28.5 | $ 26.2 | 3.68 % | $ 1.27 B | ||
|
Anika Therapeutics
ANIK
|
54.4 | $ 9.57 | 0.1 % | $ 140 M | ||
|
Eton Pharmaceuticals
ETON
|
62.3 | $ 15.96 | -4.42 % | $ 409 M | ||
|
Evogene Ltd.
EVGN
|
62.6 | $ 1.07 | -0.51 % | $ 27.9 M | ||
|
Exelixis
EXEL
|
167 | $ 41.43 | 1.35 % | $ 12 B | ||
|
Arena Pharmaceuticals
ARNA
|
142 | - | -6.81 % | $ 3.04 B | ||
|
Axon Enterprise
AXON
|
29.9 | $ 548.8 | -2.74 % | $ 41.6 B | ||
|
Ayala Pharmaceuticals
AYLA
|
2.21 K | - | - | $ 7.46 M | ||
|
Aytu BioScience
AYTU
|
186 | $ 2.39 | 3.91 % | $ 15 M | ||
|
AstraZeneca PLC
AZN
|
265 | $ 91.03 | 1.34 % | $ 96.9 B | ||
|
Acorda Therapeutics
ACOR
|
277 | - | -24.86 % | $ 820 K | ||
|
Brickell Biotech
BBI
|
105 | - | -5.38 % | $ 6.06 M | ||
|
BeiGene, Ltd.
BGNE
|
915 | - | 0.49 % | $ 251 B | ||
|
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
199 | $ 11.36 | -1.47 % | $ 735 M | ||
|
Biogen
BIIB
|
65.4 | $ 174.34 | 0.14 % | $ 25.4 B |